LDTI — Leech-Derived Tryptase Inhibitor
A miniature inhibitor that penetrates the tryptase tetramer pore
Mechanism Disclaimer
LDTI (Leech-Derived Tryptase Inhibitor) is a remarkably small proteinase inhibitor that exploits its compact size to access a target inaccessible to all natural plasma protease inhibitors. Mast cell tryptase — a tetrameric serine protease — arranges its four active sites facing inward around a narrow central pore. Large inhibitors such as α1-proteinase inhibitor (52 kDa), antithrombin III (58 kDa), and C1 inhibitor (105 kDa) are physically excluded. At only 4,738 Da, LDTI is small enough to penetrate this pore and engage the active sites directly.
Molecular Properties
| Isoform | Molecular Weight | Structural Family | Homology |
|---|---|---|---|
| LDTI-A, LDTI-B | 4,340 Da | Non-classical Kazal-type | 55% to bdellin B3 |
| LDTI-C | 4,738 Da | Non-classical Kazal-type | 55% to bdellin B3 |
Mechanism of Tryptase Inhibition
Size-Dependent Access
Mast cell tryptase exists as a ring-shaped tetramer with four active sites oriented toward a narrow central pore (an oval pore with narrow openings of approximately 40 Å x 15 Å). LDTI's compact 4.7 kDa size allows it to enter this pore and inhibit tryptase with Ki = 1.4 nM. All natural human plasma protease inhibitors (α1-PI, AT-III, C1-INH) are too large to penetrate this pore.
N-Terminal Residue Specificity
The critical determinant for tryptase inhibition lies in the N-terminal residues. LDTI exhibits Lys1-Lys2 (positively charged), which facilitates entry into the negatively charged tryptase pore. Bdellin B3, despite 55% homology, has Asp1-Thr2 and cannot inhibit tryptase — demonstrating that two residues determine functional divergence.
Engineered Variants
Engineering Thrombin-Inhibitory Activity
The compact LDTI scaffold has been engineered to acquire novel inhibitory specificities. Variants designated 2T and 5T were created with substitutions at the reactive site loop:
Variant 2T
Moderate thrombin inhibition. Retains partial tryptase activity. Demonstrates proof of principle for LDTI scaffold engineering.
Variant 5T
Ki = 28 nM for thrombin (2.1 nM for trypsin). Acquired potent thrombin-inhibitory activity through reactive site loop redesign, demonstrating the plasticity of the Kazal-type scaffold.
Additional Biological Activities
HIV-1 Replication Inhibition
Auerswald et al. (1994) reported that recombinant LDTI blocked HIV-1 replication in HUT-78 cells at 20 μM concentration. The effect has been linked to the enzymatic activity of tryptase, a tryptase-like cellular protease implicated in HIV-1 infection (Hattori et al., 1989). Although not pursued clinically, this finding highlights the broad-spectrum serine protease activity of the LDTI scaffold.
Antiproliferative Effects
Recombinant LDTI (r-LDTI) inhibits keratinocyte and fibroblast proliferation at sub-nanomolar to nanomolar concentrations (half-maximal inhibition of tryptase-induced proliferation of about 0.1 nM for fibroblasts and about 1 nM for keratinocytes). This activity is mediated through tryptase inhibition, as mast cell tryptase is a potent mitogen for both cell types. Relevant to fibrotic and hyperproliferative skin conditions.
Clinical Relevance
Mast cell tryptase is a validated therapeutic target in multiple inflammatory and fibrotic conditions. LDTI represents a natural proof-of-concept for small-molecule tryptase inhibition.
Asthma
Tryptase drives bronchoconstriction
Pulmonary Fibrosis
Tryptase promotes fibroblast proliferation
Rheumatoid Arthritis
Synovial mast cell degranulation
Psoriasis
Tryptase-driven keratinocyte proliferation
Related Resources
Eglins b/c
Elastase and cathepsin G inhibitors.
Anti-Inflammatory Mechanisms
SGS modulation of inflammatory pathways.
Compound Reference
Complete SGS bioactive component database.
Compound Coverage Map
LDTI and tryptase inhibitors in the 200-entry leech compound catalogue.
Research Roadmap
Engineered LDTI variants and the leech tryptase-inhibitor pipeline.